CDC Foundation Active Programs

October 1, 2022 - September 30, 2023

This document provides a list of CDC-led CDC Foundation programs that were active between October 1, 2022, and September 30, 2023. Each program listing includes program name, description, funding partner(s), dates for the programs and amounts of the funding provided during the fiscal year. Where applicable, funding partners from previous years are listed. Note that the dates used for active projects match CDC's fiscal year and not the CDC Foundation's fiscal year, which runs July 1 through June 30. (The CDC Foundation's not previous years of providing transparent data on external funders contributing to CDC-led and/or CDC-initiated programs. For a listing of the CDC Foundation's dones and gifts partner information, please see the CDC Foundation's septor to Congress linked from our website.)



CDC Fiscal Year 2023 Funding Partner Start Date End Date **Program Description** Cash Cumulative Funding (All Years) Program Name Committed Award (* Indicates a funding partner in CDC fiscal year) To assist countries with developing costed, funded plans that address the gaps identified by the World Health Organization-led Joint External Evaluation (JEE) process, with the goal of helping 7/1/2017 2/28/2023 Accelerating Development of Global Costed Plans countries reach compliance with the International Health Regulations. The CDC Foundation and \$3,722,127.00 CDC will support eight countries as they develop draft costed plans and help them identify funding o implement the plans. International Union Against Tuberculosis and Lung Disease Vital Strategies o perform Human Herpesvirus-8 (HHV-8) diagnostics on specimens from a University of Californ 9/1/2015 Ongoing AIDS and Kaposi's Sarcoma in Uganda San Francisco study on antiretroviral therapy for patients with AIDS and Kaposi's sarcoma in \$63,000.00 Joanda. Jniversity of California, San Francisco To provide laboratory support for the analysis of immunogenicity and shedding of new oral 10/1/2020 9/30/2026 Analysis of Immunogenicity and Shedding of New Oral Poliovirus Vaccines \$8,469,798.00 Poliovirus vaccines in human clinical trials and related issues for polio endgame. \$5,796,108.00 3ill & Melinda Gates Foundation* To pilot the training of scientists at the first PARMA (President's Malaria Initiative-supported 11/12/2021 11/30/2023 Antimalarial Resistance Monitoring in Africa \$1,499,999.00 timalarial Resistance Monitoring in Africa) site in Africa in Senegal. Bill & Melinda Gates Foundation To optimize interventions and tools to enable the elimination and eradication of prioritized 9/20/2019 3/31/2026 Biomarker Discovery through Serum Epitope Repertoire Analysis (SERA) \$4,792,434.00 eglected Tropical Diseases (NTDs) as identified by the London Declaration. Bill & Melinda Gates Foundation* \$1,852,002.00 To design and implement a high-quality comprehensive nationally representative micro-nutrient 7/3/2019 12/31/2023 Burkina Faso Micronutrient Survey \$2,000,000.00 tatus household survey in Burkina Faso. Bill & Melinda Gates Foundation To support the characterization of non-rotavirus viral diarrheal pathogens to inform the body of 10/20/2021 12/31/2024 Characterization of Non-Rotavirus Viral Diarrheal Pathogens \$1,183,158.00 ork that contributes to optimizing the efficacy of rotavirus vaccines. Bill & Melinda Gates Foundation 2/28/2023 Cholera Surveillance in Haiti To strengthen the surveillance system for the elimination of cholera in Haiti. \$620,400.00 6/22/2020 Norld Health Organization To implement and evaluate the feasibility of a care and treatment model for persons infected with \$439,252.74 7/17/2015 Chronic Hepatitis B Virus Infection in Tanzania Ongoing ronic hepatitis B virus in resource-limited settings. Gilead Sciences, Inc. To create comprehensive documentation on effective and efficient country engagement 4/2/2020 9/30/2023 Consolidating Tuberculosis Analytics and Evidence Tools \$709,180.00 pproaches for tuberculosis data and evidence-related activities Bill & Melinda Gates Foundation To develop data that will contribute to an assessment of whether transgenic mosquitoes could be 6/1/2020 1/31/2025 Controlling Mosquito Vectors of Malaria \$2,080,222,99 fectively and safely deployed to control natural populations of malaria vectors. Imperial College London* \$815,887,49 To continue project in cryopreservation and suppression of female development in mosquitoes to 7/21/2023 8/31/2025 Cryopreservation and artificial insemination for Anopheles mosquitoes \$900,000.00 ssist research for malaria control Good Ventures Foundation* \$900,000.00 To continue implementation of a cryptococcal meningitis screen and treat program in nine African 12/12/2019 Ongoing Cryptococcal Screening and Treatment \$1,948,482.00 ountries to preemptively treat patients and avoid potential infection or death. fizer Inc. o improve educational outcomes for refugee, internally displaced or host community girls and adolescent girls in humanitarian contexts, post-conflict, and host countries through technical 3/8/2023 11/30/2024 Data for Change II \$83,244.00 assistance provided for the implementation of a humanitarian Violence Against Children and Youth Survey in refugee settlements in Uganda, with special attention to sexual and gender-based violence and barriers to girls? education. Fogether for Girls, Inc.* \$83,244.00 To assist 25 low- and middle-income countries across Latin America, Asia and Africa in 3/1/2015 3/31/2024 Data for Health \$64,586,222,15 strengthening their public health data systems and data use for critical policy-making decisions. \$896.15 Bloomberg Philanthropies* Collection of birth and death data through surveys in focus countries to help improve data use by 4/1/2023 3/31/2025 Data for Health, Phase 5 \$16,700,000.00 overnment agencies and public health professionals. Bloomberg Philanthropies* \$16,700,000.00 To use a public-private partnership model that includes significant collaboration among three 6/13/2019 Digital Bridge Information Exchange between Healthcare Sector and Public Health major stakeholder communities (healthcare providers, healthcare information technology vendors \$4,788,828.00 Ongoing and public health) to promote crucial health data interoperability. ergey Brin Family Foundation

	•			CDC Fiscal Year 2023			
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
11/1/2019	3/31/2023	Early Childhood Nutrition Surveillance Optimization	To optimize surveillance and measurement of early child health by adding questions on diet, feeding practices, screen-time and/or activity to the National Survey of Children's Health, and to assess the availability of training products or tools for early care and education or home visiting settings on appropriate measurement of key child behaviors and healthy growth.				\$2,454,033.00
9/1/2019	12/31/2024	Eliminating Lymphatic Filariasis in American Samoa	To stop the spread of lymphatic filariasis and alleviate the suffering of those impacted by providing technical support to the department of health with the goal of eliminating lymphatic filariasis in American Samoa by 2025.	Robert Wood Johnson Foundation			\$1,000,000.00
11/11/2019	12/31/2023	EmPOWERED Health Program	To improve cancer outcomes by educating and empowering people to become proactive participants in their own health and improve patient-physician conversations and shared decision making.	Margaret A. Cargill Philanthropies			\$2,395,684.00
8/1/2020	7/31/2023	Environmental Control of SARS-CoV-2 in Food Establishments	To provide an evidence base for the food service industry to help navigate the COVID-19 pandemic.	Amgen Inc.* University of Arkansas at Little Rock	\$395,684.00		\$214,588.00
3/1/2020	11/30/2023	Evaluating and Improving WASH Efforts in Niger	To increase access to effective water, sanitation and hygiene (WASH) infrastructure in healthcare facilities in Niger.	WorldVision Inc.			\$121,562.00
9/16/2022	9/30/2024	Evaluating HPV Vaccine Induced Antibodies in Botswana	To evaluate the impact of HPV vaccines and the persistence of HPV antibodies among HPV- vaccinated women living with HIV in Botswana.	Bill & Melinda Gates Foundation			\$513,703.00
2/22/2021	5/31/2027	Evaluating the Impact of the Pneumococcal Conjugate Vaccine Introduction in Indonesia	To conduct an evaluation before and two years after the introduction of the Pneumococcal conjugate vaccines (PCV) to study the direct and indirect impact of PCV introduction on vaccine- type pneumococcal carriage among healthy Indonesian children under five years of age.	Copan Diagnostics, Inc.*	\$888.00		\$2,850,019.00
9/30/2021	9/30/2024	Evaluating Tuberculosis Preventive Treatment in People Living with HIV	To determine the impact of Tuberculosis preventative treatment among populations living with HIV.	Bill & Melinda Gates Foundation*	\$552,233.00		\$4,766,680.00
2/1/2019	1/31/2024	Evaluation of Malaria Specimen Bank - Phase III-VI	To analyze blood samples to determine what species of human malaria parasites are present in the specimens as part of an evaluation of a global malaria specimen bank.	Bill & Melinda Gates Foundation World Health Organization			\$1,623,746.84
3/30/2020	12/31/2023	Evaluation of Malaria Vaccine Implementation	To evaluate the feasibility, impact and safety of RTS,S/AS01E malaria vaccine implementation through routine health systems in moderate to high malaria transmission settings in sub-Saharan Africa.				\$9,533,898.00
11/3/2018	6/30/2025	Evaluation of Pneumococcal Conjugate Vaccine Schedule Change	To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.	World Health Organization*	\$1,294,142.00		\$3,712,566.00
5/16/2022	9/6/2024	Expanding Firefighting Personal Protective Equipment Cleaning Validation Procedures	To lessen firefighter exposure to harmful contaminants from uncleaned or improperly cleaned personal protective equipment (PPE) that improves firefighter safety and health.	Bill & Melinda Gates Foundation*	\$1,100,000.00		\$270,841.00
11/1/2008	9/30/2024	Field Epidemiology Training Program (FETP) in Saudi Arabia - Phase II	To evaluate Saudi Arabia's infectious disease surveillance system, help train local and regional disease detectives and improve the country's capacity to monitor for and respond to infectious disease outbreaks.	The Fire Protection Research Foundation			\$4,880,191.08
4/3/2022	4/2/2025	Field Epidemiology Training Program (FETP) in Qatar	To assist the Ministry of Public Health in establishing a Field Epidemiology Training Program (FETP) in Qatar focused on building its public health workforce capacity.	Kingdom of Saudi Arabia Ministry of Health State of Qatar Ministry of Public Health			\$2,311,663.00
6/1/2012	Ongoing	Folate Status in the United Kingdom Population	To determine folate status across the United Kingdom in order to establish a population baseline should mandatory folic acid fortification proceed.	MRC Human Nutrition Research*	\$13,974.12		\$706,502.09
7/1/2022	12/31/2025	GAVI Alliance Partner Engagement Framework (2022-2025) - Foundational Support	To coordinate the programmatic implementation of Gavi's 2022-2025 Partners' Engagement Framework, leading to increased equitable use of vaccines in lower-income countries.	Gavi Alliance			\$1,034,000.00
10/1/2022	12/31/2025	GAVI Alliance Partner Engagement Framework (2022-2025) - Strategic Focus Area	This funding will help implement the CDC Foundation programs and activities supporting the Strategic Focus Area (SFA) portion of the 2022-2025 Partners Engagement Framework.	Gavi Alliance*	\$1,456,000.00		\$3,443,848.80
10/1/2022	12/31/2024	GAVI Alliance Partner Engagement Framework (2022-2025) - TCA	To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners? Engagement Framework.	Gavi Alliance*	\$1,406,315.68		\$1,406,315.68
12/20/2017	12/19/2022	Global Cardiovascular Health Partnership	To strengthen the global evidence base of the management of cardiovascular diseases; improve point-of-care testing; and monitor trends within the global noncommunicable disease burden.				\$2,729,108.00
8/21/2019	Ongoing	Global Pediatric Norovirus Surveillance Network	To develop a Global Pediatric Norovirus Laboratory Surveillance Network to monitor norovirus strains and provide data critical for decision-making related to norovirus vaccination.	Amgen Inc.			\$339,000.00

					CDC Fiscal Year 2	023	
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Takeda Vaccines, Inc.	+20,000,00		
				Vaxart, Inc.* Individual Contributor	\$20,000.00		
			To generate knowledge on the globally spreading Streptococcus pneumoniae (pneumococcal)				
2/1/2020	11/30/2024	Global Pneumococcal Sequencing 2.0	lineages that may drive serotype replacements in pneumococcal pneumonia and changes in the prevalence of antibiotic resistance in the post-PCV13 era.				\$644,163.00
				Wellcome Sanger Institute			
2/1/2018	12/31/2022	Global Road Safety Clearinghouse and Evaluation Lab	To launch an information clearinghouse and evaluation lab for global road safety partners and champions interested in evaluating their programs and/or identifying evidence-based practices for implementation in the field.				\$97,960.05
				FIA Foundation			
6/15/2016	6/26/2023	Global Rotavirus and Invasive Bacterial Vaccine Preventable Diseases (IBVPD) Reference Laboratory	To help CDC serve as a global reference laboratory for rotavirus and the invasive bacterial vaccine preventable diseases (IBVPD) laboratory networks, which provide support to the WHO-coordinated global rotavirus and the global IBVPD surveillance networks.				\$471,846.00
				World Health Organization			
1/1/2019	Ongoing	Healthy Homes, Healthy People on Navajo Nation	To reduce the incidence of the rodent-borne disease hantavirus among residents of the Navajo Nation by preventing exposure to the virus through empowering residents to repair and reinforce their homes against rodents, notably deer mice, the vector species for hantavirus.				\$100,000.00
				Reckitt			
7/1/2022	11/30/2023	HEAR HER Expansion: American Indian/Alaska Native and Global Formative Work	To expand the reach of Hear Her resources for healthcare professionals and American Indian and Alaska Native communities in the United States and to conduct exploratory formative work to determine the feasibility of a new segment of the campaign to reach a global audience.				\$626,662.50
				Merck Sharp & Dohme Corp.			
				Individual Contributor	1		
12/1/2020	11/30/2025	HIV Prevention Trials Network	To evaluate the efficacy of injectable pre-exposure prophylaxis (PrEP) for HIV-uninfected cisgender				\$5,022,280.00
12/ 1/ 2020	11/00/2020		men and transgender women who have sex with men.	FHI 360*	\$2,979,302.00		\$5,622,200,000
1/1/2022	3/10/2023	Home-Based PrEP for Youth	To evaluate a model of oral HIV pre-exposure prophylaxis (PrEP) implementation for youth that includes home PrEP (with fewer in-person clinic visits and a telemedicine approach). The objective is to evaluate the safety, acceptability of and adherence to home-based daily oral PrEP among young men who have sex with men and transgender women.	FHL 300*	\$2,979,302.00		\$289,274.00
				American Foundation for AIDS Research (amfAR)			
10/1/2022	3/31/2024	Horizon	To assess in vivo safety and pharmacokinetics of CAB/LNG hydrogel implants placed				\$92,133.00
			subcutaneously in the back of 8 normal cycling female pigtailed macaques for up to 6 months.	Eastern Virginia Medical School*	\$92,133.00		
12/1/2009	Ongoing	Hormone Laboratory Collaborations	To help CDC provide reference and quality control materials for laboratory collaboration, including collaborations for the Hormone Measurement Standardization program.	-	<i>492,133.00</i>		\$7,104,461.48
				Abbott Ireland			
				Abbott Laboratories			
				Abbott Standard Diagnostics, Inc.			
				Academic Hospital Paramaribo Affimedix, Inc.			
				American Association for Clinical Chemistry, Inc.*	\$3,894,73		\$75,554,73
				American Association for Cambra Chemistry, Inc.	35,054.75		\$75,557.75
				Ann & Robert H. Lurie Children's Hospital of Chicago			
				Annar Diagnostica			
				ARUP Laboratories			
				Beckman Coulter			
				Bioamoy International Limited Biohit Laboratory Services			
				Bio-Rad Laboratories, Inc.			
				BioReference Laboratories, Inc.	1		
				BMH Holdings LLC			
				Boditech Med Inc.	1		
				Boston Children's Hospital			
				Boston Medical Center			
				Brigham and Women's Hospital			
				Calbiotech Inc. Cardiff and Vale University Health Board			
				Cardin and vale University Health Board Centre Hospitalier Universitaire of Liege	1		
				Centre of Reproductive Medicine and Andrology of the University			
				CEQAL	1		
				Cerilliant Corporation	İ		
				Chemux Bioscience, Inc.			
				Chromesystems Instruments & Chemicals GmbH			
				Chungnam National University	ł		
				Cleveland Clinic Clinical Pathology Laboratories, Inc.			
				Cinical Facilology Laboratories, Inc.	1		1

		CDC Fisc					
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				College of American Pathologists			
				College of American Pathologists Foundation			
				Copenhagen University Hospital			
				Covance Central Laboratory Services			
				Craft Technologies, Inc. Diagnostic Lab for Endocrinology			
				Diagnostics Biochem Canada Inc.			
				DiaSorin			
				DiaSource Immunoassays SA			
				Diazyme Laboratories			
				Douglass Hanly Moir Pathology			
				Endoceutics, Inc.			
				Endocrine Sciences Inc.			
				Epitope Diagnostics, Inc.			
				Erasmus MC Rotterdam Esoterix, Inc.			
				Eurofins Biomnis			
				Euroimmun Medizinische Labordiagnostika AG			
				Fujirebio Diagnostics, Inc.			
				Gangnam Severance Hospital, Yonsei University			
				Government of Canada			
				Green Cross Laboratories (GC Labs)			
				Grupo Fleury			
				Hasselt University			
				Health Canada			
				Heartland Assays LLC			
				IBL International			
				IDS Immunodiagnostic Systems SA Immundiagnostik AG			
				Immundiagnostic AG			
				Imperial Health Charity*	\$71,660.00		
				InSource Diagnostics	+/		
				inVentiv Health Clincial Lab Inc.			
				Johns Hopkins University			
				Kaiser Permanente			
				Kansas City VA Medical Center			
				King Saud University			
				Konkuk University of Medicine and Medical Center			
				Laboratoire National de Metrologie et D'essais			
				Laboratorios Ruiz Laboratory Alliance of Central New York			
				Laboratory Corporation of America Holdings			
				Leiden University Medical Center			
				Los Angeles Biomedical Research Institute			
				Mayo Clinic			
				Mayo Foundation for Medical Education and Research			
				MCL A Co-Tenancy Laboratory			
				Memorial Sloan-Kettering Cancer Center			
				Microgenics Corporation		L	
				Micromass UK Ltd		I	
				Monobind Inc.		ļ	
				NanoEnTek Inc.			
				New England Research Institutes, Inc. Oklahoma State University			
				Opko Diagnostics, LLC		-	
				Ortho-Clinical Diagnostics		t	
				Partners HealthCare System, Inc.	1	1	
				Pathology Associates Medical Laboratories		1	
				Penn State University Hershey Medical Center			
				Pennington Biomedical Research Foundation			
				PPD Development, LP			
				QLoudLab SA			
				Qualigen, Inc.			
				Quest Diagnostics Incorporated		l	
				Quest Diagnostics Nichols Institute Valencia	-	ļ	
				Quidel Corporation	_		
	I	1		RCPA Quality Assurance Programs Pty Limited	1	I	L

	-			CDC Fiscal Year 2023			
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Reprosource Fertility Diagnostics			
				Roche Diagnostics Corporation			
				Sahlgrenska University Hospital SCIEX			
				Sciex Seoul Medical Science Institute			
				Siemens Healthcare Diagnostics, Inc.			
				Siemens USA			
				Snibe Diagnostics (Snibe Co., Ltd.)			
				Social & Scientific Systems, Inc.			
				St. Elizabeth Healthcare			
				State of Maryland			
				Syneos Health			
				Taylor Technology, Inc. The Hong Kong Polytechnic University			
				The Pennsylvania State University			
				The University of Hong Kong			
				The University of Western Australia			
				Theranos			
				Thermo Fisher Scientific			
				Tosoh Bioscience, Inc.			
				Tosoh Corporation			
				Tricore Reference Laboratories			l
				University College Cork University Hospitals Birmingham NHS Foundation Trust			
				University of Birmingham			
				University of California, San Francisco			
				University of Copenhagen			
				University of Helsinki			
				University of Hong Kong			
				University of Maryland Medical Center			
				University of Maryland, Baltimore			
				University of Massachusetts Amherst University of Minnesota			
				University of Washington			
				Virginia Commonwealth University Health System			
				VU University Medical Center Amsterdam			
				Waters Technologies Corporation			
				Waters Technologies Ireland Ltd.			
				XCellAssay, LLC			
				Zeus Scientific, Inc.			
				Zhejiang Disigns Diagnostics			
			To help CDC provide reference and quality control materials for laboratory collaboration, including	ZRT Laboratory, LLC			
8/1/2016	Ongoing	Hormone Laboratory Collaborations 2.0	collaborations for the Hormone Measurement Standardization program.				\$435,372.57
				National Institutes of Health			
			To provide a case-control study comparing naturally occurring group B strep antibodies in young				
10/1/2018	12/31/2024	Immunologic Endpoints Against Young Infant Group B Streptococcal Disease	infants with invasive disease versus controls that will establish antibody thresholds associated with				\$5,030,468.00
			protection and inform decisions about future maternal Group B Streptococcus vaccine licensure.	Bill & Melinda Gates Foundation			
				St. George's, University of London			
11/20/2016	12/21/2022	Turungk Assessment of Datasius Vessian in D-1-1-1	To provide evidence about the public health impact and benefits on child health after the		1	1	¢2 021 067 00
11/28/2016	12/31/2023	Impact Assessment of Rotavirus Vaccine in Pakistan	introduction of rotavirus vaccine into the Pakistan National Immunization Program system.				\$2,021,967.00
				Bill & Melinda Gates Foundation			
10/14/2022	0/21/2024	Impact of CDC-Tuborculocic Provontativo Treatment Studies	To enhance the informativeness and impact of the CDC-Tuberculosis Preventative Treatment			1	¢202 991 00
10/14/2022	8/31/2024	Impact of CDC-Tuberculosis Preventative Treatment Studies	studies by funding technical experts to partner in the production of updated protocols, updated statistical analysis plans, and a multi-country meta-analysis				\$202,881.00
				Bill & Melinda Gates Foundation*	\$202,881.00		
10/1/2021	0/30/2025	Implementation and Monitoring of Overdose Prevention Programs and Policies	To develop a technical package for states to reduce overdose deaths and indicators for state		,	1	\$5,145,000.00
10/1/2021	3/ 30/ 2023	Amplementation and Promoting of Overaose Prevention Programs and Poncles	progress for overdose death prevention.			ļ	φ 3,173,000.00
			To improve to align of booltheous acception of info-theory (IAT-) - more supported to (I	Bloomberg Philanthropies*	\$2,630,000.00		
			To improve tracking of healthcare-associated infections (HAIs) across community and healthcare settings by developing an innovative process and methods for linking and analyzing data that			1	
9/11/2019	6/30/2024	Improved Tracking of Healthcare-Associated Infections	spans inpatient and community exposures and healthcare utilization in order to identify			1	\$2,874,284.00
			opportunities for prevention and early recognition.				
				Pfizer Inc.			
12/15/2021	7/31/2024	Improving Engagement in Community Level Data Collection	To improve the nation's access to community-relevant and nationally significant data that measure health and equity				\$2,027,005.80
			health and equity.	Robert Wood Johnson Foundation		1	
	1	1			1	1	I

	1			CDC Fiscal Year 2023			
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
1/1/2020	7/31/2024	Improving Testing Protocol for Inhibitors in Hemophilia	To determine whether inhibitor testing can be more efficiently, cost-effectively and accurately executed.				\$372,441.20
				Genentech, Inc.			
4/1/2018	12/31/2023	Improving Understanding of Drowning in Africa	To improve understanding of the types and circumstances of drowning in Sub-Saharan Africa in order to develop, inform and implement drowning prevention programs to mitigate drowning risks and save lives.				\$2,420,000.00
				Bloomberg Philanthropies			
5/5/2022	6/1/2024	Improving Water, Sanitation and Hygiene Services in Healthcare Facilities	To expand CDC's strategic engagement in learning and evaluation of best practices for water, sanitation and hygiene (WASH) in healthcare facilities through implementation of targeted action research pilots in Uganda.				\$200,000.00
				Wallace Genetic Foundation			
9/20/2019	8/1/2025	Indian Rotavirus Vaccines in Early Adopter Countries	To show the health impact of low-cost, Indian-made rotavirus vaccines in high burden, low-income countries of Africa and Asia.				\$1,673,274.00
				Bill & Melinda Gates Foundation			
7/6/2020	12/31/2023	Innovations in Antenatal and Postnatal Care in Kenya	To strengthen pregnancy surveillance and service delivery as part of the antenatal and postnatal care research collective at the Child Health and Mortality Prevention Surveillance site in Kenya.				\$874,113.00
				Bill & Melinda Gates Foundation			
11/15/2019	10/31/2023	Integrated Serosurveillance Center and Serologic Surveillance in Nigeria	To scale capacity for integrated serosurveillance in Africa and to conduct integrated serologic surveillance using stored samples from Nigeria's HIV Impact Survey.				\$2,199,500.00
				Bill & Melinda Gates Foundation			
11/5/2019	12/31/2022	Integrating Genomic Data Surveillance in Senegal	To scale and integrate genomic epidemiology approaches into real world malaria control and				\$177,596.00
1.1	1.1.1		elimination surveillance and decision-making strategy in Senegal, a malaria endemic country.	Harvard University T.H. Chan School of Public Health			, ,
4/1/2023	3/31/2024	Investigating Long-Acting PrEP Formulations	To investigate long-acting PrEP formulations in macaque subjects.				\$6,531.00
1/ 1/ 2020	5/51/2021			University of North Carolina at Chapel Hill*	\$6,531.00		\$0,001100
6/27/2022	12/30/2024	Investigating Safety and Efficacy of L9LS Monoclonal Antibodies in Western Kenya	To investigate novel interventions such as monoclonal antibodies (MAbs) against malaria. An intervention that could prevent malaria in children for a full 12 months in settings of perennial malaria transmission, such as Kenya, holds potential to reduce malaria morbidity and mortality				\$4,946,789.00
			substantially in this population at risk for severe malaria and death.				
			To show the solution of the second state of th	Bill & Melinda Gates Foundation			
6/1/2018	6/30/2025	Laboratory Surveillance for Pneumococcal Meningitis in India	To strengthen laboratory surveillance for pneumococcal meningitis and serotyping in India to understand the impact of a pneumococcal conjugate vaccine rollout.				\$1,031,740.00
				Bill & Melinda Gates Foundation			
6/30/2020	12/31/2023	Leveraging WHO Rotavirus Surveillance Networks for Diarrheal Pathogens	To leverage World Health Organization (WHO) global rotavirus surveillance by using novel technology to achieve a better understanding of the role of enteric pathogens other than rotavirus in childhood diarrhea requiring hospitalization.				\$679,867.71
				World Health Organization*	\$66,000.00		
8/1/2015	12/6/2022	Making Dialysis Safer for Patients	To reduce potentially deadly bloodstream infections in hemodialysis outpatients by targeting patients, healthcare providers and caregivers using evidence-based communications strategies with prevention messages.				\$456,000.00
				Amgen Inc.			
3/1/2022	3/31/2025	Maternal and Reproductive Health in Tanzania Sustainability Evaluation	To evaluate the sustainability of activities supporting increased availability and access to obstetric care, family planning and comprehensive reproductive health care in Tanzania.				\$2,700,000.00
				Bloomberg Philanthropies			
12/1/2021	5/31/2023	MATRIX	To evaluate a novel intravaginal ring to prevent HIV infection combined with a contraceptive to prevent unintended pregnancy. MATRIX stands for Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence.				\$117,757.50
				Oak Crest Institute of Science*	\$36,195.00		
2/20/2023	10/31/2025	Measles-Rubella Microarray Patch Evaluation	To evaluate the safety, tolerability and immunogenicity of a Measles-Rubella Microarray Patch (MR- MAP)				\$473,867.00
				PATH*	\$473,867.00		
3/5/2020	2/29/2024	Mechanisms of Norovirus Protective Immunity	To screen a subset of human and mouse monoclonal antibodies for their ability to neutralize GI.1, a time ordered panel of GII.4 and GII.3 noroviruses using a novel human intestinal enteroid cell culture system.				\$357,840.00
				University of North Carolina at Chapel Hill*	\$90,000.00		
10/1/2013	3/31/2024	MenAfriNet Meningitis Surveillance in Africa (MenAfriNet II)	To improve scientific understanding of meningitis to guide research on new vaccines and				\$4,999,999.00
		,	strategies, and to optimize impact of existing vaccines in the African meningitis belt.	Bill & Melinda Gates Foundation			
2/18/2020	9/30/2023	Microneedle Patch for Measles and Rubella Vaccination	To support the continuing development of a dissolving microneedle patch for measles and rubella vaccination. This patch is designed to be easily administered as a single dose by minimally trained personnel, to generate no sharps waste and to improve stability outside of the cold chain, enabling				\$370,035.00
			house-to-house campaigns and improving routine and campaign vaccination coverage.	Pill & Molinda Cates Foundation			
12/1/2019	12/31/2023	Million Hearts 2020	To provide a health communication campaign related to heart disease education and prevention in the United States with the goal of informing Americans ages 35-64 of the risk factors of heart disease and stroke and inspiring action.	Bill & Melinda Gates Foundation			\$11,300,000.00
				Amgen Inc.			
				Bayer Corporation			

					CDC Fiscal Year 2	023	
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
7/1/2019	6/30/2023	Monitoring E-Cigarette Use Among Youth	To implement a three-pillar strategy of pre- and post-measurements to complement existing surveillance activities and assess e-cigarette policy impact. The proposed pillars are: 1) adding more nuanced key indicators to state-based youth surveillance systems; 2) accessing real-time data on retail sales of e-cigarettes; and 3) leveraging longitudinal web-based surveys.				\$13,700,000.00
4/7/2020	12/31/2023	Monitoring Health Outcomes of Assisted Reproductive Technology	To provide research support for analysis of outcomes of assisted reproductive technologies.	Bloomberg Philanthropies			\$662,072.00
				Open Philanthropy Project Fund			
6/1/2019	9/30/2025	Monitoring Malaria Treatment in the United States	To collect, manage and analyze data on the safety and efficacy of tafenoquine (Krintafel) used for anti-relapse therapy of malaria in the United States.				\$139,299.00
1/1/2007	12/31/2022	Monitoring the Global Tobacco Epidemic	To support the Bloomberg Initiative to Reduce Tobacco Use by creating, launching and implementing components of the Global Tobacco Surveillance System (GTSS) as well as capacity enhancement for tobacco control programs in high-burden tobacco use countries.	GlaxoSmithKline Biologicals S.A.			\$113,559,140.00
				Bloomberg Philanthropies			
				Emory University Various Individual Contributors			
9/1/2016	Ongoing	Mosquito Cryopreservation and Female Elimination	To support cryopreservation and suppression of female development in mosquitoes to assist research for malaria control.	Good Ventures Foundation			\$2,931,437.78
				Open Philanthropy Project Fund			
10/28/2019	Ongoing	Multi-Center Zoliflodacin Study	To evaluate the efficacy of a single oral dose of zolifodacin in treatment of patients with uncomplicated gonorrhea.				\$846,434.63
			To support implementation of the mobile phone survey in Casablanca and Mumbai as an extension	Global Antibiotic Research & Development Partnership (GARDP Foundation)			
8/15/2019	Ongoing	NCD MPS implementation Mumbai and Casablanca	of the Bloomberg Philanthropies Data for Health initiative.				\$200,000.00
			To expedite the implementation of newborn screening for spinal muscular atrophy to prevent	Vital Strategies			
8/1/2018	10/31/2024	Newborn Screening of Spinal Muscular Atrophy	childhood death and disability.				\$1,500,000.00
				Biogen MA Inc.			
7/1/2022	11/30/2023	Next Generation Multipurpose Intravaginal Ring Technology Using Innovative CLIP	To evaluate the safety, pharmacokinetics (PK), and efficacy of macaque-sized CLIP 3D printed intravaginal rings (IVRs) loaded with the potent antiretroviral Islatravir® (EFdA) when administered vaginally to pigtailed macaques.				\$178,987.00
			au and so the effective set of each orthology of the second s	University of North Carolina at Chapel Hill*	\$178,987.00		
11/23/2015	11/28/2023	Opt-Out Chlamydia Screening Effectiveness	To explore the effectiveness of opt-out chlamydia screening via electronic health record prompt and to increase the percentage of women under the age of 25 who are screened for chlamydia at clinical encounters.				\$709,002.00
				Hologic Inc.			
9/1/2021	8/31/2024	Origin of Innate Immunity Suppression	To further research how viral ovarian tumor protease (vOTU) activity is critical for replication and host tropism of nairoviruses.				\$357,326.22
			To develop cell culture and small animal models of Nipah virus replication and pathogenesis in a	University of California, Riverside			
7/20/2022	6/30/2025	Pathogenic Paramyxovirus Replication in BSL-4 Containment	biosafety level (BSL) 4 lab.				\$2,791,302.00
				Bill & Melinda Gates Foundation			
9/20/2019	3/19/2023	Per- and Polyfluoroalkyl Substances Firefighter Exposures and Toxicity	To understand and assess firefighters' exposure to per- and polyfluoroalkyl substances (PFAS) and its impact.				\$131,532.00
			To produce and discominate high quality, small area health data that some see the Devulation	The University of Arizona			
11/1/2022	10/31/2024	PLACES: Local Data for Better Health	To produce and disseminate high-quality, small-area health data that compose the Population- Level Analysis and Community Estimates (PLACES) public health data resource.				\$1,399,700.00
			To support the introduction of a shance in Duding Facels infant ansumerscal usering schedule to	Robert Wood Johnson Foundation*	\$1,399,700.00		
4/5/2019	3/31/2024	Pneumococcal Conjugate Vaccine Surveillance and Evaluation in Burkina Faso	To support the introduction of a change in Burkina Faso's infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country's capacity to control pneumococcal disease among children and adults.				\$3,824,907.00
			To manife officiality, and and an information of the second state of the second state of the second state of the	Bill & Melinda Gates Foundation			
1/1/2020	12/31/2023	Preventing Child Sexual Abuse in Youth-Serving Organizations	To provide effective, evidence-based guidance for proactively protecting children and youth from sexual abuse in youth-serving organizations.				\$1,012,095.00
				Oak Foundation			
				Porticus Foundation World Childhood Foundation USA			
7/1/2021	7/31/2025	Preventing Global Child Sexual Abuse	To strengthen the evidence base for primary prevention of youth- or adult-perpetrated child sexual abuse.				\$5,785,842.00
				Oak Foundation			
6/3/2021	6/30/2022	Preventing Infections in Cancer Patients - Support During and After COVID	To develop a comprehensive campaign focusing on preventing infections in cancer patients by targeting patients, their families and their providers to reduce their risk of infection in multiple settings (outpatient office, hospital and home).				\$350,000.00
				Amgen Inc.			
7/1/2012	Ongoing	Preventing Mother-to-Child Transmission of HIV and HBV	To help CDC increase understanding of the effectiveness of using maternal tenofovir containing combination drug during the second and third trimesters of pregnancy for the prevention of mothe to child transmission of HIV and HBV in co-infected mothers.	r			\$362,800.00
				Gilead Sciences, Inc.			
9/14/2020	9/13/2025	Preventing Older Adult Falls and Fall Injuries	To prevent and protect older adults from sustaining falls and fall-related injuries by developing and implementing a risk factor prevention program.				\$4,541,535.78
				Amgen Inc.			

	-				CDC Fiscal Year 2	023	
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
1/30/2020	6/1/2023	Preventing Rocky Mountain Spotted Fever on Tribal Lands	To provide organization and assistance with the scaling of integrated prevention methods, facilitation of training in multiple locations and coordination of numerous agencies and partners to support the prevention of Rocky Mountain Spotted Fever (RMSF) in highly-impacted communities in the Southwest United States.				\$400,000.00
				PetSmart Charities, Inc.			
9/1/2018	6/30/2023	Public Health and Safety Partnerships to Reduce Opioid Overdose	To equip states and localities with the tools necessary to prevent and respond to opioid overdoses through coordination of public health and public safety.				\$2,000,000.00
				Bloomberg Philanthropies			
9/23/2021	6/30/2024	Rotavirus Vaccine Effectiveness and Safety in Nigeria and Indonesia	To strengthen sentinel rotavirus surveillance in Nigeria and Indonesia and enable monitoring of trends in rotavirus hospitalizations pre- and post-vaccine introduction in order to observe the impact of rotavirus vaccines and serve as a platform for case-control evaluations of rotavirus vaccine effectiveness.				\$1,087,608.00
				Bill & Melinda Gates Foundation			
9/17/2023	8/31/2027	Rotavirus Vaccine Effectiveness in Indonesia	To support vaccine impact, effectiveness, and safety studies of rotavirus vaccine introduced and rolled out across all regions of Indonesia.				\$3,035,396.00
			To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers,	Bill & Melinda Gates Foundation*	\$3,035,396.00		
4/1/2022	12/31/2025	Rotavirus Vaccine Impact and Effectiveness Assessments	To ensure impact and enectwelless of rotavitus valcines and sustain valcine use by poirty markets, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.	0			\$745,009.00
			To generate Respiratory Syncytial Virus (RSV) genomic surveillance data from low- and middle-	Gavi Alliance			
12/4/2019	4/30/2024	RSV Genomic Surveillance Leveraging the Global Influenza Surveillance and Response System	income countries leveraging the RSV Global Influenza Surveillance and Response System (GISRS) platform.				\$2,084,731.00
				Bill & Melinda Gates Foundation			
4/3/2015	7/31/2024	Sickle Cell Data Collection	To build the framework for collecting data about individuals in the United States with sickle cell disease in order to monitor their health outcomes, evaluate current systems of care and inform the development of a comprehensive care model to meet the needs of these individuals throughout their life.				\$3,870,636.00
				Biogen MA Inc.			
				Bioverativ Inc. Doris Duke Charitable Foundation, Inc.			
				Global Blood Therapeutics, Inc.			
				Novartis US Foundation			
				Pfizer Inc.			
				Sanofi Genzyme	1075 000 00		
9/1/2017	6/30/2023	Strengthening Global Cardiovascular Health Systems	To promote technical exchange through establishment and improvement of public health surveillance systems, laboratory testing and training to enhance public health initiatives related to cardiovascular disease.	Vertex Pharmaceuticals Incorporated*	\$275,000.00 \$7,363,979.00	\$7,363,979.00	
				International Union Against Tuberculosis and Lung Disease			
				Vital Strategies			
10/1/2019	9/30/2024	Strengthening Global Cardiovascular Health Systems Phase II	To reduce the burden of cardiovascular diseases in low- and middle-income countries by providing technical expertise, facilitating technical packages, building Field Epidemiology Training Program (FETP) workforce capacity, establishing a consortium of experts and collaborating with governmental agencies and partners.				\$4,503,000.00
			To support chemistry, manufacturing and control (CMC) and preclinical development of an	Bloomberg Philanthropies			
8/27/2022	7/31/2025	Support for Inactivated Rotavirus Vaccine	inactivated rotavirus vaccine.				\$1,277,615.00
				Bill & Melinda Gates Foundation			
4/16/2021	10/31/2023	Support for Malaria Control and Elimination in Tanzania	To establish local molecular, genetics and genomic laboratory and analytical capacity to support malaria surveillance in Tanzania.				\$318,700.00
				National Institute for Medical Research (Tanzania)			
11/1/2017	6/30/2024	Supporting Water and Hygiene Infrastructure in Africa	To implement a two-phased approach to provide short- and long-term solutions to the problem of inadequate water, sanitation and hygiene infrastructure in low-resource settings in Burkina Faso, Ethiopia, Ghana and Uganda.				\$1,700,000.00
				Conrad N. Hilton Foundation			
12/1/2021	12/1/2024	Technical Assistance for Pneumococcal Carriage Study Burkina Faso	To assess the impact of the Pneumococcal conjugate vaccine catch up campaign among internally displaced populations in the northern Sahel region of Burkina Faso. This effort will implement and evaluate the impact of changing the pneumococcal conjugate vaccine schedule.				\$347,273.00
				Davycas International*	\$27,272.24		
8/1/2014	3/31/2023	Tobacco Control Surveillance in Africa	To create a standard surveillance system to monitor tobacco use and key tobacco control measures across Sub-Saharan Africa. The data will enhance and strengthen tobacco control research and policy capacity in low- and middle-income countries, where the emergence of a tobacco epidemic is a concern.				\$8,966,710.00
				Bill & Melinda Gates Foundation			
12/7/2009	Ongoing	Together for Girls	To enable CDC to work with individual countries and regions to quantify the problem of sexual violence against girls and subsequently develop evidence-based policies and programs to protect children and prevent violence.				\$1,826,783.80
				BD Henry Schein Cares Foundation			
	I	1		menny Schelli Cares Foundation	1		1

					CDC Fiscal Year 2		
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Nduna Foundation			
				United Nations Development Programme			
				Various Individual Contributors			
7/1/2023	6/30/2025		To support efforts to improve data around drowning incidents in the US, provide basic swimming and water safety skills training in US areas with a high burden of drowning, and support findings from Ghana and India on circumstances of drowning.				\$6,000,000.00
				Bloomberg Philanthropies*	\$6,000,000.00		
8/1/2019	7/31/2024		To understand the rectal muscosal effects of cross-sex hormone therapy among U.S. and Thai transgender women.				\$709,203.00
				Emory University*	\$179,044.00		
4/15/2020	12/31/2022	Using Benchmarks to Improve Joint External Evaluation Scores	To identify, implement and track health security activities in three countries and improve joint external evaluation (JEE) scores.				\$1,021,995.00
				Vital Strategies			
6/1/2016	10/31/2023	Vector Stock and Reagent Repository for Research	To maintain, produce, authenticate and distribute arthropod vectors and associated reagents for the Microbiology and Infectious Diseases Biological Research Resources (MID-BRR) Program.				\$3,633,739.96
				American Type Culture Collection*	\$240,012.97		
7/1/2018	12/31/2027	Z-CAN: Finish Strong	To complete the Zika Contraceptive Access Network (Z-CAN) through data collection, evaluation and dissemination.				\$400,000.00
				Bayer U.S. LLC			